StreetInsider.com News Articles

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Wed, 15 Jul 2026 16:05:00 -0400

CHASKA, Minn., July 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that effective on July 13, 2026, Lifecore granted a restricted stock unit (“RSU”) award with respect to 3,500 shares of its common stock under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) to a newly hired employee of Lifecore.

The RSU award was granted pursuant to the offer letter between Lifecore and the employee, and as a material inducement to the employee joining Lifecore. The RSU award was approved by

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Wed, 15 Jul 2026 16:05:00 -0400

The RSU award was granted pursuant to the offer letter between Lifecore and the employee, and as a material inducement to the employee joining Lifecore. The RSU award was approved by

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Wed, 15 Jul 2026 16:05:00 -0400

The RSU award was granted pursuant to the offer letter between Lifecore and the employee, and as a material inducement to the employee joining Lifecore. The RSU award was approved by

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Wed, 15 Jul 2026 16:05:00 -0400

The RSU award was granted pursuant to the offer letter between Lifecore and the employee, and as a material inducement to the employee joining Lifecore. The RSU award was approved by

Form SCHEDULE 13D/A LIFECORE BIOMEDICAL, Filed by: Legion Partners Asset Management, LLC

Thu, 02 Jul 2026 17:37:00 -0400

si-local-file:///var/storage/secattach/20260702/26729706.html

Form SCHEDULE 13D/A LIFECORE BIOMEDICAL, Filed by: Legion Partners Asset Management, LLC

Thu, 02 Jul 2026 17:37:00 -0400

si-local-file:///var/storage/secattach/20260702/26729706.html

Form SCHEDULE 13D/A LIFECORE BIOMEDICAL, Filed by: Legion Partners Asset Management, LLC

Thu, 02 Jul 2026 17:37:00 -0400

si-local-file:///var/storage/secattach/20260702/26729706.html

Form 8-K LIFECORE BIOMEDICAL, For: Jun 29

Thu, 02 Jul 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260702/26729509.html

Form 8-K LIFECORE BIOMEDICAL, For: Jun 29

Thu, 02 Jul 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260702/26729509.html

Form 8-K LIFECORE BIOMEDICAL, For: Jun 29

Thu, 02 Jul 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260702/26729509.html

Form SCHEDULE 13D/A LIFECORE BIOMEDICAL, Filed by: 22NW Fund, LP

Thu, 02 Jul 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260702/26729458.html

Form SCHEDULE 13D/A LIFECORE BIOMEDICAL, Filed by: 22NW Fund, LP

Thu, 02 Jul 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260702/26729458.html

Form SCHEDULE 13D/A LIFECORE BIOMEDICAL, Filed by: 22NW Fund, LP

Thu, 02 Jul 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260702/26729458.html

Lifecore Biomedical signs manufacturing deal for neurology product

Mon, 15 Jun 2026 07:05:11 -0400

Lifecore Biomedical Inc. (NASDAQ: LFCR) announced it signed an agreement with an unnamed global pharmaceutical company to provide technical transfer services and commercial manufacturing for an injectable suspension product treating neurological disorders.

The Chaska, Minnesota-based contract development and manufacturing organization will handle production of the higher-viscosity suspension formulation for the currently marketed neurology product. The company said this marks its seventh late-stage program agreement in seven months.

"Being selected to produce this higher-viscosity suspension formulation demonstrates confidence in Lifecore's technical know-how and exceptional quality track record," said Paul Josephs, chief executive officer of Lifecore, according to the press release.

Lifecore specializes in sterile

Lifecore Biomedical signs manufacturing deal for neurology product

Mon, 15 Jun 2026 07:05:11 -0400

Lifecore specializes in sterile

Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company

Mon, 15 Jun 2026 07:05:00 -0400

--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product--

--Seventh Addition to Lifecore’s Late-Stage Pipeline in Seven Months--

CHASKA, Minn., June 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced it has signed a new agreement with a global pharmaceutical company. Under the terms of the agreement, Lifecore will perform technical transfer services to support the commercial production of an injectable suspension product for neurological disorders.

“With this significant new customer win, we have

Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company

Mon, 15 Jun 2026 07:05:00 -0400

--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product--

--Seventh Addition to Lifecore’s Late-Stage Pipeline in Seven Months--

“With this significant new customer win, we have

Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company

Mon, 15 Jun 2026 07:05:00 -0400

--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product--

--Seventh Addition to Lifecore’s Late-Stage Pipeline in Seven Months--

“With this significant new customer win, we have

Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company

Mon, 15 Jun 2026 07:05:00 -0400

--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product--

--Seventh Addition to Lifecore’s Late-Stage Pipeline in Seven Months--

“With this significant new customer win, we have

Form 4 LIFECORE BIOMEDICAL, For: Jun 04 Filed by: Legion Partners Holdings, LLC

Mon, 08 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260608/26617939.html

Form 4 LIFECORE BIOMEDICAL, For: Jun 04 Filed by: Legion Partners Holdings, LLC

Mon, 08 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260608/26617939.html

Form 4 LIFECORE BIOMEDICAL, For: Jun 04 Filed by: OBUS NELSON

Fri, 05 Jun 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260605/26611876.html

Form 4 LIFECORE BIOMEDICAL, For: Jun 04 Filed by: OBUS NELSON

Fri, 05 Jun 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260605/26611876.html

Form 4 LIFECORE BIOMEDICAL, For: Jun 04 Filed by: Korenberg Matthew E

Fri, 05 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260605/26611865.html

Form 4 LIFECORE BIOMEDICAL, For: Jun 04 Filed by: Korenberg Matthew E

Fri, 05 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260605/26611865.html